Compare AU
Compare CURE vs. IISV
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Intell Investor Select Value Shr Fund - Active ETF (IISV). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | IISV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 11 |
Median incremental investment | $619.50 | $665.13 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $4,559.49 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | IISV | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | IISV.AX was created on 2023-03-31 by Intelligent Investor . The fund's investment portfolio concentrates primarily on total market equity. The portfolio aims to outperform the S&P/ASX 200 Accumulation Index p.a. over five year rolling periods with minimal turnover to allow returns to compound in a favourable tax environment |
Top 3 holdings | Natera Inc (3.41 %) Incyte Corp (2.94 %) Gilead Sciences Inc (2.88 %) | RPMGlobal Holdings Ltd (7.77 %) Fairfax Financial Holdings Ltd Shs Subord.Vtg (6.95 %) KKR & Co Inc Ordinary Shares (5.57 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Financials (50.65 %) Consumer Discretionary (15.93 %) Information Technology (14.85 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | United States (42.65 %) Australia (20.03 %) United Kingdom of Great Britain and Northern Ireland (15.60 %) |
Management fee | 0.45 % | 0.97 % |
Key Summary
CURE | IISV | |
|---|---|---|
Issuer | Global X | Intelligent Investor |
Tracking index | S&P Biotechnology Select Industry | S&P/ASX 200 Accumulation Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.97 % |
Price | $49.94 | $3.51 |
Size | $38.065 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.24 % | 0.07 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 30/03/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | IISV | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 11 |
Median incremental investment | $619.50 | $665.13 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,323.41 | $4,559.49 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | IISV | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | IISV |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |